ECM
ZVRA icon

Endurant Capital Management’s Zevra Therapeutics ZVRA Stock Holding History

Endurant Capital Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-10,599
Closed -$2.46M – 95
2016
Q1 		$2.46M Buy
10,599
+4,044
+62% +$979K 0.8% 39
2015
Q4 		$2.08M Buy
6,555
+2,634
+67% +$715K 0.7% 44
2015
Q3 		$1.22M Sell
3,921
-5,185
-57% -$1.59M 0.41% 55
2015
Q2 		$2.68M Buy
+9,106
New +$1.99M 0.79% 38

Other funds holding ZVRA

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Endurant Capital Management's ZVRA Position: Q2 2016 in Review

Endurant Capital Management sold out of Zevra Therapeutics (ZVRA) in Q2 2016, closing a stake of 10,599 shares — an estimated $2.46M sold.

Endurant Capital Management first reported a position in ZVRA in Q2 2015 and held it in 4 quarters. The position peaked at $2.68M in Q2 2015. 40 funds tracked by Wall St. Rank hold ZVRA as of Q2 2016.

  • Endurant Capital Management reported no remaining Zevra Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Endurant Capital Management sold 10,599 Zevra Therapeutics shares in Q2 2016, an estimated $2.46M.
  • Endurant Capital Management first reported a position in Zevra Therapeutics in Q2 2015 and held it in 4 quarters.
  • Endurant Capital Management's Zevra Therapeutics position peaked at $2.68M in Q2 2015.
  • 40 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2016.

Based on Endurant Capital Management's 13F filing for Q2 2016, filed 15 Aug 2016.